AstraZeneca to Invest $3.5 Billion in the US

Anglo-Swedish drugmaker AstraZeneca plans to invest $3.5 billion in the US to expand the company’s research and manufacturing footprint by the end of 2026.

The investment includes a new R&D center in Cambridge, Massachusetts, a manufacturing facility for biologics in Maryland and expanded capacities for the production of cell therapies on the West and East Coast as well as for the manufacture of specialty products in Texas.

Pascal Soriot, CEO of AstraZeneca, said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”

AstraZeneca said that the planned investments in the US are part of its ambition to achieve $80 billion in total revenue by 2030. According to AstraZeneca, the US is its largest market, generating 44% of total revenue.

© David Porter / AstraZeneca
© David Porter / AstraZeneca

Company

Logo:

AstraZeneca

Byggrad 2/4
15185 Södertälje
Sweden

Company contact







Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.